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Key Points
• Nausea and vomiting are classic symptoms in patients with gastroparesis. Most studies combine nausea and
vomiting into one symptom complex; there may be different characteristics relating to nausea as compared
vomiting. There may be different characteristics of these symptoms in diabetic compared to idiopathic
gastroparesis.
• Nausea is present in essentially all patients with gastroparesis irrespective of cause. Nausea is associated with
decreased quality of life in patients with gastroparesis. Vomiting was more prevalent, more severe, and occurred
more often in diabetic compared to idiopathic gastroparesis.
• The characteristics of vomiting differ in idiopathic vs diabetic gastroparesis.
Abstract
Background Nausea and vomiting are classic symp-
toms of gastroparesis. It remains unclear if character-
istics of nausea and vomiting are similar in different
etiologies of gastroparesis. The aims of this article
were as follows: to describe characteristics of nausea
and vomiting in patients with gastroparesis and to
determine if there are differences in nausea and
vomiting in diabetic (DG) and idiopathic gastroparesis
(IG). Methods Gastroparetic patients enrolling in the
NIDDK Gastroparesis Registry underwent assessment
with history and questionnaires assessing symptoms,
quality of life, and a questionnaire characterizing
nausea and vomiting. Key Results Of 159 gastropare-
sis patients (107 IG, 52 DG), 96% experienced nausea,
whereas 65% experienced vomiting. Nausea was pre-
dominant symptom in 28% and vomiting was pre-
dominant in 4%. Nausea was severe or very severe in
41%. PAGI-SYM nausea/vomiting subscore was
greater with increased vomiting severity, but not
nausea severity in DG than IG. Nausea was related
to meals in 71%; lasting most of the day in 41%.
Increasing nausea severity was related to decreased
quality of life. Nausea often preceded vomiting in 82%
of patients and vomiting often relieved nausea in 30%.
Vomiting was more common in DG (81%) compared
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to IG (57%; p = 0.004). Diabetic patients more often
had vomiting in the morning before eating, during the
night, and when not eating. Conclusions & Inferences
Nausea is present in essentially all patients with
gastroparesis irrespective of cause and associated with
decreased quality of life. In contrast, vomiting was
more prevalent, more severe, and occurred more often
in DG than IG. Thus, characteristics of vomiting differ
in IG vs DG.
Keywords diabetic gastroparesis, gastric emptying,
gastroparesis, Nausea, vomiting.
INTRODUCTION
Nausea and vomiting are classic symptoms in
patients with gastroparesis.1 While most patients
experience some degree of nausea, only some gastro-
paresis patients have vomiting with some studies
suggest vomiting is seen in less than 50% of patients
with gastroparesis.2 Studies have suggested that nau-
sea and vomiting symptoms correlate with worse
quality of life in gastroparesis patients.3,4 Despite the
importance of nausea and vomiting in gastroparesis,
the characteristics of these symptoms have not been
well described.
Nausea and vomiting may have different manifes-
tations in different etiologies of gastroparesis. Some
studies have suggested that nausea and vomiting are
more severe in diabetic gastroparesis (DG) than
idiopathic gastroparesis (IG).3–5 Most studies combine
nausea and vomiting into one symptom complex;
there may be different characteristics relating to
nausea as compared vomiting. There may be different
characteristics of these symptoms in diabetic com-
pared to IG. The potential differential perception of
nausea in diabetic vs IG might be due to different
pathophysiological mechanisms and the effects of
diabetes on neuronal function. This has important
treatment implications for nausea and vomiting in
patients with diabetic and IG.
The aims of this study were to describe character-
istics of nausea as compared to vomiting in patients
with gastroparesis and to determine if there are
differences between two etiologies of gastroparesis –
DG and IG. We also aimed to better understand the
relationship between nausea and vomiting in gastro-
paresis, determine if nausea and vomiting impact on
the impaired quality of life in gastroparesis, and




The NIDDK Gastroparesis Clinical Research Consortium is a
cooperative network of eight academic motility centers and one
Data Coordinating Center (DCC).5,6 The Gastroparesis Registry 2
(ClinicalTrials.gov Identifier: NCT01696747) was implemented as
an observational study of patients with gastroparesis enrolled
prospectively at eight centers. This study uses data from the
second gastroparesis registry, which was designed, in part, to
enhance the understanding of symptoms and physiologic dys-
function in patients with gastroparesis. There was a special
emphasis to look at the symptoms of nausea and vomiting
through a Nausea and Vomiting Questionnaire which was
designed to assess the clinical characteristics of both nausea and
vomiting.
Study patients
Gastroparetic patients were enrolled at eight centers into the NIH
Gastroparesis Registry from September 2012 to August 2015.
Enrolled patients met specific entry criteria being 18 years or
older with symptoms of at least 12 weeks duration, delayed
gastric emptying scintigraphy (GES) within 6 months of enroll-
ment, and no structural abnormality as seen by upper endoscopy
within 1 year of enrollment.
This report focuses on patients with either idiopathic or DG.
The diabetic patients could have either type 1 diabetes mellitus
(T1DM) or type 2 diabetes mellitus (T2DM) as defined by the
physician and/or patient. The diagnosis of patients with the
idiopathic etiology was based on no previous gastric surgery, no
diabetes history (before or after the onset of gastroparesis at
enrollment), a normal hemoglobin A1C, and no other known
etiologies.
All studies were approved by the Institutional Review Board at
each Clinical Center and at the DCC.
Study protocol
During face-to-face interviews with each subject, the study
physicians or coordinators at each Clinical Center completed
case report forms including data relating to gastroparesis disease
onset, symptoms, disease profile, associated medical conditions,
including diabetes, and medication and supplemental therapies.
The study physicians performed a comprehensive physical exam-
ination. Laboratory measures were obtained, including hemoglo-
bin A1C values, antinuclear antibody (ANA), and erythrocyte
sedimentation rate (ESR).
The clinical severity of gastroparesis was graded on a scale
originally reported in the American Neurogastroenterology and
Motility Society (ANMS) review on treatment of gastroparesis.7
The severity was graded as grade 1: mild gastroparesis (symptoms
relatively easily controlled and able to maintain weight and
nutrition on a regular diet); grade 2: compensated gastroparesis
(moderate symptoms with only partial control with use of daily
medications, able to maintain nutrition with dietary adjust-
ments); grade 3: gastroparesis with gastric failure (refractory
symptoms that are not controlled as shown by the patient having
ER visits, frequent doctor visits or hospitalizations and/or inabil-
ity to maintain nutrition via an oral route).
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Each patient filled out the 20 item Patient Assessment of
Upper Gastrointestinal Symptoms (PAGI-SYM) questionnaire
which assesses symptoms of gastroparesis, dyspepsia, and gas-
troesophageal reflux disease8; it includes the nine symptoms of
the Gastroparesis Cardinal Symptom Index (GCSI) which asks
about nausea, retching, vomiting, stomach fullness, inability to
finish a meal, excessive fullness, loss of appetite, bloating, and
abdominal distension.9 The GCSI equals the mean of the nausea/
vomiting subscore, postprandial fullness/early satiety subscore,
and bloating subscore where: Nausea/vomiting subscore = mean
of the scores for nausea, retching, and vomiting; Postprandial
fullness/early satiety sub-score = mean of the scores for stomach
fullness, inability to finish meal, excessive fullness, and loss of
appetite; and Bloating subscore = mean of the scores for bloating
and large stomach. The PAGI-SYM also inquires about symptoms
of gastroesophageal reflux including daytime heartburn, heartburn
lying down, daytime chest discomfort, nighttime chest discom-
fort, daytime reflux, nighttime reflux, and bitter taste. In the
PAGI-SYM, patients are asked to assess the severity of their
symptoms during the previous 2 weeks using a 0–5 scale where no
symptoms = 0, very mild = 1, mild = 2, moderate = 3, severe = 4,
and very severe = 5.
Disease-specific quality of life was assessed by the Patient
Assessment of Upper Gastrointestinal Disorders-Quality of Life
(PAGI-QOL) survey, which scores 30 factors from 0 (none of the
time) to 5 (all of the time).10 Patients were asked how often
gastrointestinal problems they may be experiencing have affected
different aspects of their quality of life and well-being in the past
2 weeks. Overall PAGI-QOL scores were calculated by taking
means of all subscores after reversing item scores; thus a mean
PAGI-QOL score of 0 represents poor quality of life, whereas 5
reflects the best life quality.
The Medical Outcomes Study 36-Item Short-Form Health
Survey version 2 (SF-36v2) was additionally used to assess the
patients’ views of overall physical and mental health in the past
4 weeks (standard recall form). The eight subscales were stan-
dardized to the 1998 U.S. general population with a mean (SD) of
50  10. Physical and mental health summary measures were
computed. A higher score reflects higher quality of life.11
A Nausea and Vomiting Questionnaire was designed to assess
the clinical characteristics of both nausea and vomiting. Part of
this questionnaire is a modification of the Nausea Profile
characterizing nausea in three dimensions: somatic distress, GI
distress, and emotional distress.12 This questionnaire had
previously been modified for capturing nausea related to
gastroparesis.3
Gastric emptying scintigraphy
Gastric emptying scintigraphy was performed using a low-fat, egg
white meal with imaging at 0, 1, 2, 4 h after meal ingestion, as
described by a published multicenter protocol13 and endorsed by
the Society of Nuclear Medicine and ANMS.14 This protocol
ensures standardized information about gastric emptying across
sites. In addition, liquid gastric emptying in the presence of solids
was assessed using Indium-111.15
Patients were instructed to stop medications that could affect
gastrointestinal motility for the 72 h prior to the study and to
come to the Nuclear Medicine Section in the morning after
fasting overnight with nothing to eat after midnight, that is, an
8 h fast. Gastric emptying scintigraphy was performed using a
standard low-fat, Eggbeaters meal to measure solid empty-
ing.13,14 The meal consisted of the equivalent of two large eggs
radiolabeled with Tc-99m sulfur colloid served with two pieces of
white bread and jelly. In addition, patients were given 120 mL
water radiolabeled with In-111 diethylene triamine pentacetic
acid for the measurement of liquid gastric emptying. Following
ingestion of the meal, imaging was performed at 0, 1, 2, 3 and 4 h
with the patient upright for measuring gastric emptying of Tc-
labeled solids and 111-In-labeled liquids. In between imaging,
patients generally sat in the nuclear medicine waiting area.
Gastric emptying was analyzed as the percent of radioactivity
retained in the stomach over time using the geometric center of
the decay-corrected anterior and posterior counts for each time
point. Gastric retention of Tc-99m >60% at 2 h and/or >10% at
4 h was considered evidence of delayed gastric emptying of solids.
Delayed gastric emptying was graded according to the gastric
retention at 4 h: mild (≤20% gastric retention at 4 h), moderate
(>20–35%), and severe (>35%).14,16 Delayed gastric emptying of
liquids in the presence of solids is greater than 50% retention of
In-111 at 1 h emptying.15
Statistical methods
Descriptive statistics (means, standard deviations, frequencies,
and percentages) were used to compare subgroups of gastroparesis
patients. Enrollment characteristics such as demographics, med-
ical history, gastroparesis history, symptom severity, and quality
of life were compared by etiology (idiopathic compared to
diabetic). P-values were determined from Fisher’s exact tests for
categorical variables and t-tests for continuous variables. Enroll-
ment characteristics were also compared by the subgroups of
nausea severity score on the PAGI-SYM instrument (none/very
mild/mild, moderate, and severe/very severe) and the subgroup of
vomiting severity score on the PAGI-SYM instrument (none, very
mild/mild/moderate, and severe/very severe). P-values were
determined from a Cochran–Armitage test for trend in nausea or
vomiting subgroups for binary variables, a Mantel–Haenszel chi-
squared test for trend in nausea or vomiting subgroups for
categorical variables, and a non-parametric Cuzick test for trend
in nausea or vomiting subgroups for continuous variables.17
Multiple logistic models were selected based on Akaike Informa-
tion criteria using forward selection of all possible models derived
from a candidate set of 16 enrollment variables (see Table 1).18,19
The resulting model for severe nausea included etiology, age, solid
gastric emptying percent at 4 h, PAGI-SYM satiety/fullness
subscore, SF-36 mental score, SF-36 physical score, and PAGI-
QOL score. The resulting model for severe vomiting included
etiology, age, race, PAGI-QOL score, HbA1c%, and the following
PAGI-SYM measures: satiety/fullness subscore, bloating sub-
score, and GERD subscore. All p-values are two-sided; values
<0.05 were considered statistically significant. Analyses were
performed using methods described in SAS version 9.3 (SAS
Institute) or Stata version 13.1 (StataCorp).20
RESULTS
Patient characteristics
One hundred and fifty-nine patients with gastroparesis
were evaluated: 107 patients with IG and 52 patients
with DG (35 with T1DM, 17 with T2DM). Average age
was 44.7  13.3 years. Females comprised the major-
ity of patients (84.9%). Table 1 contains other demo-
graphic information. The majority of patients had
compensated (grade 2) gastroparesis (66.0%) with
moderate severity of symptoms of gastroparesis (GCSI
© 2016 John Wiley & Sons Ltd1904
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Table 1 Characteristics of patients with idiopathic or diabetic gastroparesis
Characteristic
Etiology
Total (n = 159) p-value†Idiopathic (n = 107) Diabetic (n = 52)
Demographics
Gender: females 97 (90.7%) 38 (73.1%) 135 (84.9%) 0.008
Age (years) 43.6  14.0 46.9  11.8 44.7  13.3 0.14
Hispanic 9 (8.4%) 13 (25.0%) 22 (13.8%) 0.007
Race: white 98 (91.6%) 42 (80.8%) 140 (88.1%) 0.07
Gastroparesis history
Duration of symptoms (years) 6.0  6.5 8.1  7.8 6.7  7.0 0.08
Onset of gastroparesis symptoms
Acute 46 (43.0%) 20 (38.5%) 66 (41.5%) 0.50
Insidious or gradual 59 (55.1%) 32 (61.5%) 91 (57.2%)
Predominant symptom prompting gastroparesis evaluation
Nausea 37 (34.6%) 11 (21.2%) 48 (30.2%) 0.26
Vomiting 15 (14.0%) 8 (15.4%) 23 (14.5%)
Abdominal pain 24 (22.4%) 11 (21.2%) 35 (22.0%)
Other 31 (29.0%) 22 (42.3%) 53 (33.3%)
Nature of gastroparesis symptoms
Chronic, but stable 20 (18.9%) 6 (11.5%) 26 (16.5%) 0.70
Chronic, but progressive worsening 22 (20.8%) 11 (21.2%) 33 (20.9%)
Chronic, but some improvement 10 (9.4%) 8 (15.4%) 18 (11.4%)
Chronic with periodic exacerbations 37 (34.9%) 17 (32.3%) 54 (34.2%)
Cyclic pattern 16 (15.1%) 9 (17.3%) 25 (15.8%)
Asymptomatic 1 (0.9%) 1 (1.9%) 2 (1.3%)
Gastroparesis severity
Mild (grade 1) 20 (18.7%) 12 (23.1%) 32 (20.1%) 0.47
Compensated (grade 2) 74 (69.2%) 31 (59.6%) 105 (66.0%)
Gastric failure (grade 3) 13 (12.2%) 9 (17.3%) 22 (13.8%)
Weight history
BMI (kg/m2) 26.5  8.2 29.3  6.7 27.4  7.8 0.03
Medical history
Diabetes
Type 1 35 (67.3%)
Type 2 17 (32.7%)
Hospitalization for gastroparesis in the past year 22 (20.6%) 22 (42.3%) 44 (27.7%) 0.004
Number of hospitalizations for gastroparesis in the past year 2.4  1.7 7.0  11.0 4.7  8.2 0.06
Use of G tube 3 (2.8%) 0 (0.0%) 3 (1.9%) 0.55
Use of J tube 2 (1.9%) 1 (1.9%) 3 (1.9%) 1.00
Presence of central line 0 (0.0%) 4 (7.7%) 4 (2.7%) 0.01
Presence of gastric stimulator 5 (4.7%) 10 (19.2%) 15 (9.4%) 0.007
Use of prokinetics 34 (31.8%) 22 (42.3%) 56 (35.2%) 0.19
Use of Botox (ever) 28 (26.2%) 19 (36.5%) 47 (29.6%) 0.20
Use of antinausea medications 87 (81.3%) 42 (80.8%) 129 (81.1%) 1.00
Use of narcotics 87 (35.5%) 20 (38.5%) 58 (36.5%) 0.72
Use of alternative medications 53 (49.5%) 12 (23.1%) 65 (40.9%) 0.002
PAGI-SYM symptom severity (0–5)‡
Nausea score 2.9  1.6 3.0  1.6 2.9  1.6 0.64
Vomiting score 0.9  1.4 1.9  1.8 1.2  1.6 0.0001
Retching score 1.1  1.5 1.8  1.7 1.4  1.6 0.01
Nausea subscore 1.6  1.2 2.3  1.5 1.8  1.4 0.006
Satiety subscore 3.3  1.2 3.3  1.3 3.3  1.2 0.88
Bloating subsore 3.1  1.6 3.0  1.7 3.0  1.6 0.88
Cardinal symptom index (GCSI) 2.7  1.1 2.9  1.1 2.7  1.1 0.27
Upper abdominal pain subscore 2.8  1.6 2.8  1.5 2.8  1.5 0.93
GERD subscore 1.8  1.3 1.8  1.5 1.8  1.4 0.89
Predominant symptom of PAGI-SYM
Nausea 31 (29.0%) 13 (25.0%) 44 (27.7%) 0.15
Vomiting 5 (4.7%) 2 (3.9%) 7 (4.4%)
Upper abdominal pain or discomfort 18 (16.8%) 3 (5.8%) 21 (13.2%)
Other 53 (49.5%) 34 (65.4%) 87 (54.7%)
PAGI-QOL (0–5)§
Activity subscore 2.6  1.2 2.9  1.2 2.7  1.2 0.29
Clothing subscore 2.9  1.7 3.0  1.9 2.9  1.7 0.58
(Continued.)
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score of 2.7  1.1). However, 13.8% of patients were
graded as having gastric failure with 27.7% of these
patients having been hospitalized within last year.
Symptoms prompting evaluation for gastroparesis
included nausea (30.2%), vomiting (14.5%), and
abdominal pain (22.0%). At the time of enrollment in
the registry, the predominant symptoms were nausea
in 27.7% of patients, upper abdominal pain in 13.2%
and vomiting in 4.4% of patients. Antinausea medica-
tions were being used by 81.1% of the patients,
prokinetics agent use in 35.2%, and narcotic analgesics
by 36.5%. Other treatments included gastric electric
stimulator in 9.4% of patients, use of G tube in 1.9%,
use of J tube in 1.9%, and presence of a central line in
2.7%. Overall the gastric emptying was moderately
delayed with 30.0% retention at 4 h, being more
delayed in DG (37.1% retention) than IG (26.5%
retention; p = 0.0009). For the diabetic patients, the
average HgbA1c was 8.3  2.0% with 53.9% of the
diabetic patients having HgbA1c ≥8.0%. There was a
decreased quality of life in the patients with gastro-
paresis most prominently with the SF-36 physical
score being 33.7 compared to normal of 50.
Nausea/Vomiting severity using PAGI-SYM
Table 1 compares the PAGI-SYM symptom severity
between diabetic and idiopathic patients. The nausea/
vomiting subscore of the PAGI-SYM (average of
nausea, retching, and vomiting severity) was greater
in diabetic (2.3  1.5; p = 0.006) than idiopathics
(1.6  1.2) with increased vomiting severity in diabetic
(1.9  1.8; p = 0.0001) than idiopathic (0.9  1.4) and
increased retching severity in diabetics (1.8  1.7) than
idiopathic (1.1  1.5; p = 0.01). Nausea severity was
not different between IG and DG (3.0  1.6 for diabetic
vs 2.9  1.6 for idiopathic (p = 0.64).
Table 2 shows characteristics of patients with gas-
troparesis according to their nausea severity as
assessed using the PAGI-SYM. Nausea severity was
severe or very severe in 65 of 159 (41%) patients (42 of
107 [40%] IG and 23 of 52 [45%] IG; p = 0.77). The
severity of retching and vomiting increased as nausea
severity increased. The severity of other symptoms of
gastroparesis also tracked with the severity of nausea:
satiety/fullness subscore (p < 0.0001), bloating sub-
score (p = 0.002), upper abdominal pain subscore
(p < 0.0001), and GERD subscore (p = 0.03).
Increasing nausea was related to decreased quality of
life by PAGI-QOL (p = 0.005), especially in the activity
subscore (p < 0.001), diet subscore (p = 0.005), and
relationship subscore (p = 0.01). Increasing nausea
was associated with decreased quality of life using
the SF-36: SF-36 physical (p = 0.01) and mental
(p = 0.03) measures.
There was a trend for increasing antiemetic use
(p = 0.04) and narcotic use (p = 0.06) with increasing




Total (n = 159) p-value†Idiopathic (n = 107) Diabetic (n = 52)
Diet subscore 1.6  1.3 2.2  1.4 1.8  1.3 0.006
Relationship subscore 3.4  1.2 3.3  1.5 3.3  1.3 0.56
Psychology subscore 3.3  1.3 3.1  1.5 3.2  1.4 0.39
Total PAGI-QOL 2.8  1.0 2.9  1.3 2.8  1.1 0.47
SF-36v2 Health Survey (past 4 weeks)¶
Physical health summary measure 33.7  9.7 33.8  11.4 33.7  10.2 0.94
Mental health summary measure 43.0  13.5 41.1  13.8 42.4  13.6 0.41
Solid gastric scintigraphy
Percent retention at 1 h 79.3  13.8 80.8  12.6 79.8  13.3 0.51
Percent retention at 2 h 63.0  16.3 64.7  19.0 63.6  17.2 0.58
Percent retention at 4 h 26.5  16.5 37.1  22.3 30.0  19.1 0.0009
Liquid gastric scintigraphy
Percent retention at 30 min 63.1  17.3 68.6  17.4 65.0  17.4 0.19
Percent retention at 1 h 49.1  16.6 50.8  19.7 49.7  17.6 0.66
Nausea/vomiting severity is a subscale from the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM). It is
the average of the nausea, retching, and vomiting severity scores. †The significance of difference in categorical variables between groups was tested
with a chi-squared test or Fisher’s exact test. Continuous variables were analyzed with a t-test. All p-values are two-sided. ‡Subscales derived from the
Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM). A higher score reflects a greater severity. §Subscales
derived from the Patient Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL). Scales have been recoded so that a higher score
reflects a higher QOL. ¶Scores on the Medical Outcomes Study 36-Item Short-Form Health Survey V2 (SF-36v2) standard recall were normalized to the
1998 U.S. general population with a mean (SD) of 50  10. A higher score reflects higher QOL or better health outcome. Data are means  SD or
number (percents).
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Table 2 Characteristics of patients with idiopathic or diabetic gastroparesis by nausea severity
Characteristic
Nausea severity on PAGI-SYM*
Total










Idiopathic 34 (66.7%) 31 (72.1%) 42 (64.6%) 107 (67.3%) 0.77
Diabetic 17 (33.3%) 12 (27.9%) 23 (35.4%) 52 (32.7%)
Demographics
Gender: females 45 (88.3%) 35 (81.4%) 55 (84.6%) 135 (84.9%) 0.62
Age (years) 48.3  13.8 43.0  13.4 41.0  12.1 44.7  13.3 0.001
Hispanic 11 (21.6%) 3 (7.0%) 8 (12.3%) 22 (13.8%) 0.18
Race: white 49 (96.1%) 38 (88.4%) 53 (81.5%) 140 (88.1%) 0.02
Gastroparesis history
Nature of gastroparesis symptoms
Chronic, but stable 10 (19.6%) 7 (16.3%) 9 (14.1%) 26 (16.5%) 0.95
Chronic, but progressive worsening 6 (11.8%) 11 (25.6%) 16 (25.0%) 33 (20.9%)
Chronic, but some improvement 11 (21.6%) 4 (9.3%) 3 (4.7%) 18 (11.4%)
Chronic with periodic exacerbations 15 (29.4%) 13 (30.2%) 26 (40.6%) 54 (34.2%)
Cyclic pattern 7 (13.7%) 8 (18.6%) 10 (15.6%) 25 (15.8%)
Asymptomatic 2 (3.9%) 0 (0.0%) 0 (0.0%) 2 (1.3%)
Gastroparesis severity
Mild (grade 1) 22 (43.1%) 3 (7.0%) 7 (10.8%) 32 (20.1%) <0.0001
Compensated (grade 2) 27 (52.9%) 34 (79.1%) 44 (67.7%) 105 (66.0%)
Gastric failure (grade 3) 2 (3.9%) 6 (14.0%) 14 (21.5%) 22 (13.8%)
Medical history
BMI (kg/m2) 27.8  8.8 28.3  6.4 26.5  7.9 27.4  7.8 0.30
Use of prokinetics 14 (27.5%) 17 (39.5%) 25 (38.5%) 56 (35.2%) 0.24
Use of antiemetics 37 (72.6%) 35 (81.4%) 57 (87.7%) 129 (81.1%) 0.04
Use of narcotics 15 (29.4%) 13 (30.2%) 30 (46.2%) 58 (36.5%) 0.06
Laboratory results
HbA1c, if diabetic (%) 8.3  2.0 8.2  2.4 8.3  1.8 8.3  2.0 0.91
HbA1c ≥8.0%, if diabetic 11 (64.7%) 5 (41.7%) 12 (52.2%) 28 (53.9%) 0.48
ANA negative, if idiopathic 26 (76.5%) 29 (93.6%) 36 (85.7%) 91 (85.1%) 0.30
ESR, if idiopathic 15.6  13.0 15.3  10.3 12.8  12.6 14.4  12.0 0.28
ESR elevated >30 mm, if idiopathic 6 (17.7%) 4 (12.9%) 2 (5.0%) 12 (11.4%) 0.09
PAGI-SYM symptom severity (0–5)‡
Nausea score 0.9  0.9 3.0  0.0 4.4  0.5 2.9  1.6 <0.001
Vomiting score 0.4  0.9 1.2  1.3 1.9  1.9 1.2  1.6 <0.001
Retching score 0.4  0.8 1.3  1.2 2.1  1.8 1.4  1.6 <0.001
Nausea/vomiting subscore 0.5  0.7 1.8  0.7 2.8  1.2 1.8  1.4 <0.001
Satiety/fullness subscore 2.5  1.3 3.3  0.9 3.9  1.0 3.3  1.2 <0.001
Bloating subscore 2.4  1.8 3.2  1.4 3.4  1.5 3.0  1.6 0.002
Cardinal symptom index (GCSI) 1.8  1.0 2.8  0.7 3.4  0.8 2.7  1.1 <0.001
Upper abdominal pain subscore 2.0  1.7 2.7  1.2 3.4  1.4 2.8  1.5 <0.001
GERD subscore 1.4  1.4 2.1  1.3 2.0  1.4 1.8  1.4 0.03
Predominant symptom from the PAGI-SYM
Nausea 2 (3.9%) 12 (27.9%) 30 (46.2%) 44 (27.7%) 0.08
Vomiting 1 (2.0%) 1 (2.3%) 5 (7.7%) 7 (4.4%)
Upper abdominal pain or discomfort 6 (11.8%) 4 (9.3%) 11 (16.9%) 21 (13.2%)
Other 42 (82.4%) 26 (60.5%) 19 (29.2%) 87 (54.7%)
PAGI-QOL (0–5)§
Activity subscore 3.2  1.1 2.6  1.1 2.3  1.2 2.7  1.2 <0.001
Clothing subscore 3.2  1.8 2.8  1.5 2.8  1.9 2.9  1.7 0.27
Diet subscore 2.3  1.5 1.7  1.2 1.5  1.2 1.8  1.3 0.005
Relationship subscore 3.7  1.3 3.2  1.3 3.1  1.3 3.3  1.3 0.01
Psychology subscore 3.4  1.3 3.3  1.2 2.9  1.5 3.2  1.4 0.09
Total PAGI-QOL 3.2  1.1 2.7  1.0 2.5  1.1 2.8  1.1 0.005
SF-36v2 Health Survey (past 4 weeks)¶
Physical health summary measure 36.3  10.9 34.4  9.8 31.3  9.5 33.7  10.2 0.01
Mental health summary measure 44.7  13.5 44.1  12.9 39.4  13.7 42.4  13.6 0.03
Solid gastric scintigraphy
Percent retention at 2 h 63.6  17.2 59.7  15.6 66.2  18.0 63.6  17.2 0.27
Percent retention at 4 h 29.5  19.8 23.5  14.2 34.6  20.4 30.0  19.2 0.09
(Continued.)
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similar HgbA1c values across the different severities of
nausea.
Severe or very severe nausea patients had increased
gastric retention at 4 h on the GES test (34.6%
retention for severe/very severe compared to 23.5%
for moderate, and 29.5% none/mild; p = 0.09). Severity
of nausea was not related to retention of liquids
(p = 0.36).
Table 3 shows characteristics of patients according
to their vomiting severity. Vomiting was present at the
time of enrollment in 75 of 159 patients (48%), being
present more often in DG (65%) than in IG (38%;
p = 0.002). Percentage wise, more patients with DG (11
of 52 or 21%) had severe/very severe vomiting com-
pared to IG (12 of 107 or 11%; p = 0.15). As expected,
increasing retching and nausea severity were seen with
increasing vomiting severity. Increasing vomiting
severity tracked with other symptoms of gastroparesis;
satiety subscore (p < 0.001), bloating subscore
(p = 0.002), upper abdominal pain subscore
(p < 0.001), and GERD subscore (p = 0.03). Increasing
vomiting severity was associated with worsening
quality of life on the PAGI-QOL (p = 0.005), especially
activity (p < 0.001), relationship (p = 0.01) subscores.
Increasing vomiting was associated with decreased SF-
36 physical component (p = 0.01) and mental compo-
nent (p = 0.03). In diabetic patients, HgbA1c tended to
be higher in those with more severe vomiting
(9.0  1.9%), but the trend was not significant
(p = 0.81). Use of prokinetic agents, antiemetic agents,
and narcotic analgesics increased with increasing
vomiting severity. Retention at 4 h on GES differed,
but not statistically significantly, in the vomiting
severity subgroups (p = 0.09): with 39.8% retention in
those with severe/very severe vomiting, compared to
26.6% retention for those with mild/moderate vomit-
ing, and 29.4% retention for those with no vomiting.
We further looked at the relationship of gastroparetic
symptoms with delayed gastric emptying (Table S1).
Gastric retention at 4 h was greater in diabetic than IG.
More patients with DG had severe gastric retention
than IG. Stomach fullness and postprandial fullness,
but not nausea and vomiting, were significantly
increased with increasing gastric retention at 4 h using
symptoms captured at enrollment. We also collected
symptoms at time of the gastric emptying test. As with
surveys obtained on enrollment, symptom severities
measured at the time of the gastric emptying test
showed no significant relation of nausea or vomiting to
gastric retention rates. Increasing stomach fullness was
associated with increasing gastric retention. Use of
antiemetics, but not prokinetic or narcotic analgesics,
was associated with more severe retention during
gastric emptying testing.
The gastroparesis patients were also compared
according to the 2 and 4 h gastric emptying data by
dividing the patients in three groups: (i) Delayed at 2 h,
normal at 4 h; (ii) Delayed at 2 h, delayed at 4 h; and
(iii) Normal at 2 h, delayed at 4 h. The severity of
nausea, retching, early satiety, and upper abdominal
pain were similar among these groups.
Most patients had nausea. There were 24 patients
scoring no nausea on the PAGI-SYM, 84 patients with
no vomiting on the PAGI-SYM, and 23 patients with
no nausea or vomiting. Using the nausea and vomiting
form, there were six with no nausea, 56 with no
vomiting, and six with no nausea or vomiting. The
patients with no nausea or vomiting on the PAGI-SYM
Table 2 (continued)
Characteristic
Nausea severity on PAGI-SYM*
Total









Percent retention at 4 h, diabetic patients only 37.1  26.7 32.7  19.3 39.5  20.7 37.1  22.3 0.33
Percent retention at 4 h, idiopathic patients only 25.7  14.4 20.0  9.9 31.9  20.0 26.5  16.5 0.17
Liquid gastric scintigraphy
Percent retention at 30 min 64.1  16.9 67.3  14.8 63.8  20.0 65.0  17.4 0.83
Percent retention at 1 h 49.2  19.0 52.2  13.6 48.1  19.4 49.7  17.6 0.36
*Nausea severity is a score from the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM). †The significance
of difference in binary variables between groups was tested with a Cochran–Armitage trend test, the significance of difference in categorical variables
between groups was tested with a Mantel–Haenszel chi-squared test, and the significance of difference in continuous variables between groups was
tested with a non-parametric Cuzick test for trend. All p-values are two-sided. ‡Subscales derived from the Patient Assessment of Upper
Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM). A higher score reflects a greater severity. §Subscales derived from the Patient
Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL). Scales have been recoded so that a higher score reflects a higher QOL.
¶Scores on the Medical Outcomes Study 36-Item Short-Form Health Survey V2 (SF-36v2) standard recall were normalized to the 1998 U.S. general
population with a mean (SD) of 50  10. A higher score reflects higher QOL or better health outcome. Data are means  SD or number (percents).
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Idiopathic 66 (78.6%) 29 (55.8%) 12 (52.2%) 107 (67.3%) 0.003
Diabetic 18 (21.4%) 23 (44.2%) 11 (47.8%) 52 (32.7%)
Demographics
Gender: females 75 (89.3%) 41 (78.9%) 19 (82.6%) 135 (84.9%) 0.20
Age (years) 45.4  14.1 45.2  12.4 41.0  12.5 44.7  13.3 0.001
Hispanic 11 (13.1%) 7 (13.5%) 4 (17.4%) 22 (13.8%) 0.65
Race: white 77 (91.7%) 47 (90.4%) 16 (69.6%) 140 (88.1%) 0.01
Medical history
Nature of gastroparesis symptoms
Chronic, but stable 19 (22.6%) 6 (11.8%) 1 (4.4%) 26 (16.5%) 0.17
Chronic, but progressive worsening 14 (16.7%) 13 (25.5%) 6 (26.1%) 33 (20.9%)
Chronic, but some improvement 8 (9.5%) 9 (17.7%) 1 (4.4%) 18 (11.4%)
Chronic with periodic exacerbations 31 (36.9%) 14 (27.5%) 9 (39.1%) 54 (34.2%)
Cyclic pattern 10 (11.9%) 9 (17.7%) 6 (26.1%) 25 (15.8%)
Asymptomatic 2 (2.4%) 0 (0.0%) 0 (0.0%) 2 (1.3%)
Gastroparesis severity
Mild (grade 1) 25 (29.8%) 6 (11.5%) 1 (4.4%) 32 (20.1%) <0.0001
Compensated (grade 2) 54 (64.3%) 37 (71.2%) 14 (60.9%) 105 (66.1%)
Gastric failure (grade 3) 5 (6.0%) 9 (17.3%) 8 (34.8%) 22 (13.8%)
Medical history
BMI (kg/m2) 27.7  8.6 28.1  6.9 24.8  6.3 27.4  7.8 0.30
Use of prokinetics 21 (25.0%) 21 (40.4%) 14 (60.9%) 56 (35.2%) 0.0009
Use of antiemetics 63 (75.0%) 45 (86.5%) 21 (91.3%) 129 (81.1%) 0.04
Use of narcotics 21 (25.0%) 23 (44.2%) 14 (60.9%) 58 (36.5%) 0.0005
Laboratory results
HbA1c, if diabetic (%) 8.5  1.7 7.8  2.1 9.0  1.9 8.3  2.0 0.81
HbA1c ≥8.0%, if diabetic 12 (66.7%) 9 (39.1%) 7 (63.6%) 28 (53.9%) 0.64
ANA negative, if idiopathic 54 (81.8%) 25 (86.2%) 12 (100.0%) 91 (85.1%) 0.12
ESR, if idiopathic 15.6  12.9 12.0  10.0 13.7  11.6 14.4  12.0 0.39
ESR elevated >30 mm, if idiopathic 9 (13.9%) 2 (6.9%) 1 (9.1%) 12 (11.4%) 0.41
PAGI-SYM symptom severity (0–5)‡
Nausea score 2.3  1.7 3.3  1.2 4.4  0.9 2.9  1.6 <0.001
Vomiting score 0.0  0.0 1.8  0.8 4.4  0.5 1.2  1.6 <0.001
Retching score 0.4  0.9 2.1  1.4 3.3  1.4 1.4  1.6 <0.001
Nausea/vomiting subscore 0.9  0.7 2.4  0.9 4.0  0.6 1.8  1.4 <0.001
Satiety/fullness subscore 3.0  1.3 3.5  0.9 3.9  1.2 3.3  1.2 <0.001
Bloating subsore 2.8  1.6 3.3  1.5 3.4  1.7 3.0  1.6 0.002
Cardinal symptom index (GCSI) 2.2  1.0 3.1  0.8 3.8  0.9 2.7  1.1 <0.001
Upper abdominal pain subscore 2.4  1.6 3.2  1.3 3.2  1.5 2.8  1.5 <0.001
GERD subscore 1.5  1.3 2.0  1.4 2.6  1.5 1.8  1.4 0.03
Predominant symptom from the PAGI-SYM
Nausea 20 (23.8%) 15 (28.9%) 9 (39.1%) 44 (27.7%) 0.13
Vomiting 0 (0.0%) 0 (0.0%) 7 (30.4%) 7 (4.4%)
Upper abdominal pain or discomfort 12 (14.3%) 8 (15.4%) 1 (4.4%) 21 (13.2%)
Other 52 (61.9%) 29 (55.8%) 6 (26.1%) 87 (54.7%)
PAGI-QOL (0–5)§
Activity subscore 2.9  1.1 2.6  1.2 2.1  1.1 2.7  1.2 <0.001
Clothing subscore 3.1  1.7 2.8  1.7 2.6  2.1 2.9  1.7 0.27
Diet subscore 1.9  1.4 1.8  1.3 1.3  1.1 1.8  1.3 0.005
Relationship subscore 3.6  1.2 3.1  1.5 2.9  1.4 3.3  1.3 0.01
Psychology subscore 3.4  1.2 3.1  1.5 2.7  1.5 3.2  1.4 0.09
Total PAGI-QOL 3.0  1.0 2.7  1.1 2.3  1.1 2.8  1.1 0.005
SF-36v2 Health Survey (past 4 weeks)¶
Physical health summary measure 35.5  9.6 32.0  11.1 31.1  9.8 33.7  10.2 0.01
Mental health summary measure 42.7  13.3 42.8  14.5 40.2  12.5 42.4  13.6 0.03
Solid gastric scintigraphy
Percent retention at 1 h 79.9  14.4 80.6  10.6 77.8  15.1 79.8  13.3 0.69
(Continued.)
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had a higher BMI than patients with nausea and/or
vomiting (32  11 vs 27  7; p = 0.004). There were
also significantly less other gastroparesis symptoms on
the PAGI-SYM including satiety subscore (2.3  1.4 vs
3.5  1.1; p < 0.0001) and upper abdominal pain
(1.8  1.8 vs 3.0  1.4; p = 0.001). There were similar
percentages of diabetic/idiopathic patients and similar
percent retention at 2 and 4 h between these two
groups.
Logistic regression analysis was used to look at
independent predictors of nausea and vomiting severity
(Tables 4 and 5). Severe/very severe nausea according
to the PAGI-SYM was associated with younger age,
increased satiety subscore, decreased mental SF-36
score, and decreased SF-36 physical score (Table 4).
Severe vomiting was associated with non-white race,
increased satiety subscore, decreased bloating sub-
score, and increased GERD subscore (Table 5).
Characteristics of nausea/vomiting
The characteristics of nausea and vomiting are shown
Table S2. Overall 153 of 159 patients (96.2%) experi-
enced nausea as a symptom (97.2% of idiopathics and
94.2% of diabetic patients). The nausea was lasting















Percent retention at 2 h 64.8  16.9 61.2  16.5 64.7  20.1 63.6  17.2 0.27
Percent retention at 4 h 29.4  19.4 26.6  14.7 39.8  24.2 30.0  19.1 0.09
Percent retention at 4 h, diabetic patients only 40.0  28.9 33.5  16.7 39.9  21.1 37.1  22.3 0.78
Percent retention at 4 h, idiopathic patients only 26.5  14.9 21.0  10.3 39.7  27.6 26.5  16.5 0.65
Liquid gastric scintigraphy
Percent retention at 30 min 64.1  16.7 67.3  13.6 62.8  24.7 65.0  17.4 0.83
Percent retention at 1 h 48.2  17.3 50.7  13.4 51.5  25.7 49.7  17.6 0.36
*Vomiting severity is a score from the Patient Assessment of Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM). †The
significance of difference in binary variables between groups was tested with a Cochran–Armitage trend test, the significance of difference in
categorical variables between groups was tested with a Mantel–Haenszel chi-squared test, and the significance of difference in continuous variables
between groups was tested with a non-parametric Cuzick test for trend. All p-values are two-sided. ‡Subscales derived from the Patient Assessment of
Upper Gastrointestinal Disorders Symptom Severity Index (PAGI-SYM). A higher score reflects a greater severity. §Subscales derived from the Patient
Assessment of Upper Gastrointestinal Disorders-Quality of Life (PAGI-QOL). Scales have been recoded so that a higher score reflects a higher QOL.
¶Scores on the Medical Outcomes Study 36-Item Short-Form Health Survey V2 (SF-36v2) standard recall were normalized to the 1998 U.S. general
population with a mean (SD) of 50  10. A higher score reflects higher QOL or better health outcome. Data are means  SD or number (percents).
Enrollment
characteristic
Unadjusted analyses Adjusted analyses
OR CI p† OR CI p‡
Etiology (diabetic vs idiopathic) 1.23 (0.63, 2.40) 0.55 1.12 (0.48, 2.61) 0.80
Age, years 0.96 (0.94, 0.99) 0.004 0.96 (0.93, 0.99) 0.005
Solid gastric emptying
scintigraphy, percent retention at 4 h
1.02 (1.00, 1.04) 0.01 1.02 (0.99, 1.04) 0.14
PAGI-SYM, satiety/fullness subscore 2.58 (1.76, 3.77) <0.001 2.83 (1.80, 4.44) <0.001
SF-36, mental score 0.97 (0.95, 1.00) 0.02 0.94 (0.90, 0.98) 0.006
SF-36, physical score 0.96 (0.93, 0.99) 0.01 0.95 (0.90, 0.99) 0.02
PAGI-QOL score 0.70 (0.52, 0.94) 0.02 1.75 (0.95, 3.20) 0.07
*Severe nausea defined as ‘severe’ or ‘very severe’ nausea score on the PAGI-SYM instrument.
†Unadjusted odds ratios, 95% confidence limits, p-values determined from logistic regression
models of severe nausea on each predictor. ‡Adjusted odds ratios, 95% confidence limits, p-
values were determined from a multiple logistic regression analyses of severe nausea using all
baseline predictors indicated. This model was determined from Akaike Information criteria
(AIC) with forward selection using a candidate set of baseline variables: gender, age at
enrollment, etiology, race, SF-36 physical score, SF-36 mental score, PAGI-QOL total score, solid
GES 2 h retention percent, solid GES 4 h retention percent, HbA1c, ESR, gastroparesis severity,
and the following PAGI-SYM items: satiety subscore, bloating subscore, upper abdominal pain
subscore, and GERD subscore. Etiology was forced into the model.
Table 4 Logistic regression analyses of
enrollment characteristics as predictors of
severe nausea* in idiopathic and diabetic
gastroparetics (n = 159)
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day (27.5%); whereas in 31.4% of the patients, the
nausea lasted for about an hour or less. Nausea was
related to meals in 71.2%, but felt by patients to be
unrelated to eating in 28.8%. Nausea was worse in the
morning before eating in 27.5% of patients and worse
in the evening in 26.1% of patients. Other factors that
were related to increasing nausea included high fat
meals (44.4% of patients), dairy (32.0% of patients),
being hungry (26.3%), riding in a car (25.7%). There
were no significant differences in these characteristics
of nausea between patients with DG and IG. Nausea
increasing during or after meals tended to be more
frequently reported by IG (52.4%) compared to DG
(32.7%; p = 0.06).
The nausea profile was compared between patients
with idiopathic and DG. The total nausea profile was
not significantly different between idiopathic and
diabetic patients (46.4 vs 46.5; p = 0.99); with similar
values for the somatic, GI distress, and emotional
distress subscales.
The characteristics of vomiting are also shown in
Table S2. Overall 64.8% of patients experienced vom-
iting as a symptom, being experienced more in diabetic
(80.8%) compared to idiopathic patients (57.0% of
idiopathic patients; p = 0.004). Vomiting lasted for
several minutes in 51.0% of patients, about 30 min
to several hours in 32.4%, and most of the day in
16.7% of patients; tending to be more prolonged in
diabetic than idiopathic patients (p = 0.11). Vomiting
often was related to eating (72.8% of patients), being
unrelated to eating in 27.2%. The vomitus was
described as partial digested food in 45.4% or undi-
gested food in 34.0%. Vomiting occurred in the
morning before eating more often in diabetic (69.0%)
than idiopathic patients (44.3%; p = 0.04). The vomit-
ing could wake patients up at night in 55.4% of
patients, being more prevalent in DG than IG
(p = 0.02). Nausea often preceded vomiting in 81.6%
of patients; whereas vomiting often relieved nausea in
30.1%. Vomiting could occur even if no food or drink
was take in 35.0% of patients, being more common in
diabetic (45.2%), then idiopathic patients (27.9%;
p = 0.008).
DISCUSSION
This study has carefully detailed the characteristics of
both nausea and vomiting in patients with gastropare-
sis; two important, and often considered classical
symptoms of gastroparesis. This study finds that
nausea is present in nearly all (96%) patients with
gastroparesis. Nausea was the predominant symptom
in 28% of the patients, the most common of the single
individual symptoms. Nausea was present for many
hours in the majority of patients. The characteristics of
nausea (severity, timing) were similar in diabetic and
idiopathic patients. Vomiting was present in approxi-
mately half the patients but was considered the
predominant symptoms in only a small percentage
(4%) of the patients. In contrast to nausea, vomiting
was more prevalent and severe in diabetic than in IG.
This study documents the decreased quality of life in
patients with gastroparesis. The SF-36 physical score
was 33.7 compared to normal of 50. There was less
effect on the mental quality of life with SF-36 of 42.4.
Increasing nausea and vomiting were both related to
decreased quality of life using the disease-specific
instrument PAGI-QOL. Using logistic regression anal-
ysis, nausea severity, but not vomiting severity, was
independently associated with the SF-36 QOL scores.
Thus, gastroparesis has an increased clinical burden as
demonstrated objectively by decreased quality of life,
Table 5 Logistic regression analyses of enrollment characteristics as predictors of severe vomiting* in idiopathic and diabetic gastroparetics (n = 159)
Enrollment characteristic
Unadjusted analyses Adjusted analyses
OR CI p† OR CI p‡
Etiology (diabetic vs idiopathic) 2.12 (0.87, 5.21) 0.10 1.02 (0.19, 5.59) 0.98
Age, years 0.98 (0.94, 1.01) 0.16 0.97 (0.93, 1.01) 0.16
Race (white vs non-white) 0.22 (0.08, 0.64) 0.006 0.20 (0.05, 0.80) 0.02
PAGI-SYM, satiety subscore 1.95 (1.18, 3.21) 0.009 2.17 (1.19, 3.95) 0.01
PAGI-SYM, bloating subscore 1.19 (0.89, 1.60) 0.24 0.62 (0.41, 0.95) 0.03
PAGI-SYM, GERD subscore 1.60 (1.15, 2.22) 0.005 1.77 (1.16, 2.72) 0.009
PAGI-QOL score 0.63 (0.42, 0.95) 0.03 0.71 (0.42, 1.20) 0.20
HbA1c, % 1.28 (1.04, 1.59) 0.02 1.29 (0.85, 1.95) 0.24
*Severe vomiting defined as ‘severe’ or ‘very severe’ vomiting score on the PAGI-SYM instrument. †Unadjusted odds ratios, 95% confidence limits, p-
values determined from logistic regression models of severe vomiting on each predictor. ‡Adjusted odds ratios, 95% confidence limits, p-values were
determined from a multiple logistic regression analyses of severe nausea using all baseline predictors indicated. This model was determined from
Akaike Information criteria (AIC) with forward selection using a candidate set of baseline variables: gender, age at enrollment, etiology, race, SF-36
physical score, SF-36 mental score, PAGI-QOL total score, solid GES 2 h retention percent, solid GES 4 h retention percent, HbA1c, ESR,
gastroparesis severity, and the following PAGI-SYM items: satiety subscore, bloating subscore, upper abdominal pain subscore, and GERD subscore.
Etiology was forced into the model.
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and nausea severity is associated with this decreased
quality of life. Other smaller studies have shown that
nausea and vomiting symptoms are associated with
impaired quality of life,3,4 but this study importantly
separates the characteristics of nausea and vomiting.
Nausea was present in nearly all patients with
gastroparesis, irrespective of the etiology. Nausea was
generally present for many hours in the majority of
patients. The characteristics of nausea (severity, tim-
ing) were similar in diabetic and idiopathic patients.
In contrast, vomiting was less prevalent, being present
in roughly half of patients with gastroparesis, with
significant differences in the characteristics of vom-
iting among the diabetic and idiopathic patients.
Vomiting was more common and more severe in
patients with diabetic than IG. Interestingly, diabetic
patients more often had vomiting occurring in the
morning before eating, during the night, and could
occur even if the patient did not eat. Clinically, many
patients state they do not want to vomit and limit
their intake and change diet so that do not have
vomiting. On the other hand, some patients find that
vomiting helps to relieve the nausea. Our prior study
also suggested that nausea and vomiting were more
severe in diabetic than IG.21 This study expands this
by showing it is the vomiting characteristics that
appear to be different between diabetic and IG with
the nausea being somewhat similar between the two.
The vomiting data was assessed by PAGI-SYM and
our nausea and vomiting questionnaire. In the PAGI-
SYM, vomiting severity is graded by the patient. More
recent measures of vomiting have assessed the fre-
quency and duration of vomiting episodes, instead of
the severity of vomiting. Future studies should take
these aspects into consideration in assessing vomiting
severity. We did not find a relationship of worsening
glucose control in diabetic patients with different
severities of nausea or with vomiting. Autonomic
dysfunction sometimes present in diabetic patients
may be related to the presence of vomiting. Vagal and
non-vagal pathways and several brainstem nuclei
participate in vomiting in response to different emetic
stimuli.22 Physiologic differences between idiopathic
and DG may relate to worse vagal impairments in
diabetics.23,24
Each of the symptoms of the nausea/vomiting
subscore (nausea, retching, vomiting) tracked with
each other. In addition, increasing nausea and
increasing vomiting were related to increasing sati-
ety/fullness subscore and upper abdominal pain; this
is not surprising as these are the symptoms of
gastroparesis. Satiety severity associated with nausea
severity suggests a vagal neuropathy as a possible
cause. We also found that as nausea and vomiting
increased, there was an increased use of antiemetic
agents as expected but also the use of narcotic
analgesics. Narcotics can delay gastric emptying and
cause nausea and vomiting as a side effect. Our study
demonstrates a relationship of narcotics with symp-
toms but not with delayed gastric emptying. The
relation of narcotic analgesics with nausea might be
related to the central effects of opiates rather than
their peripheral effects in slowing gastric emptying.
The results of the study show that nausea and
vomiting severity varies by gastric emptying but are
not linearly related. Our study showed increased
severity of nausea among severely delayed gastric
emptying. However, the statistical trend test for both
nausea and vomiting showed no significant systematic
relationship with gastric emptying (p = 0.09 for both).
In a previous study from our GpCRC, we did not show
a significant relationship between nausea severity and
delay of gastric emptying.25 This study included
assessment of gastric emptying using liquids as well;
however, we found that the liquid results were consis-
tent with the solid results – we did not find a
relationship between retention of liquids and symptom
severity of nausea or vomiting. The symptom assess-
ment at enrollment was not on the same day as the
gastric emptying test (median separation of 13 days,
IQR 0–95 days); however, even when symptoms at the
time of gastric emptying were assessed, only stomach
fullness, but not nausea or vomiting, appeared to be
associated with increasing delay in gastric emptying.
In conclusion, this study demonstrates that nausea
and vomiting are important symptoms of gastroparesis.
The severity of nausea is related to the decrease in
quality of life that is present in patients with gastro-
paresis. Characteristics of nausea appeared similar
between diabetic and IG. Vomiting, however, was
more prevalent and severe in DG than in IG, occurred
more often in the morning in DG, during the night and
when not eating. Thus, although characteristics of
nausea appear to be similar between diabetic and IG,
the characteristics of vomiting differ in idiopathic vs
DG. Symptoms of nausea and vomiting are important
symptoms that need to be specifically addressed,
perhaps individually, in treating patients with gastro-
paresis.
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